Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations.
biomarkers
chemotherapy
delivery of health care
diagnosis
health equity
immunotherapy
ovarian neoplasms
patient care management
quality of health care
radiotherapy
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 02 2022
15 02 2022
Historique:
revised:
29
09
2021
received:
09
08
2021
accepted:
30
09
2021
pubmed:
18
11
2021
medline:
11
3
2022
entrez:
17
11
2021
Statut:
ppublish
Résumé
The high lethality of ovarian cancer in the United States and associated complexities of the patient journey across the cancer care continuum warrant an assessment of current practices and barriers to quality care in the United States. The objectives of this study were to identify and assess key components in the provision of high-quality care delivery for patients with ovarian cancer, identify challenges in the implementation of best practices, and develop corresponding quality-related recommendations to guide multidisciplinary ovarian cancer programs and practices. This multiphase ovarian cancer quality-care initiative was guided by a multidisciplinary expert steering committee, including gynecologic oncologists, pathologists, a genetic counselor, a nurse navigator, social workers, and cancer center administrators. Key partnerships were also established. A collaborative approach was adopted to develop comprehensive recommendations by identifying ideal quality-of-care program components in advanced epithelial ovarian cancer management. The core program components included: care coordination and patient education, prevention and screening, diagnosis and initial management, treatment planning, disease surveillance, equity in care, and quality of life. Quality-directed recommendations were developed across 7 core program components, with a focus on ensuring high-quality ovarian cancer care delivery for patients through improved patient education and engagement by addressing unmet medical and supportive care needs. Implementation challenges were described, and key recommendations to overcome barriers were provided. The recommendations emerging from this initiative can serve as a comprehensive resource guide for multidisciplinary cancer practices, providers, and other stakeholders working to provide quality-directed cancer care for patients diagnosed with ovarian cancer and their families.
Identifiants
pubmed: 34787913
doi: 10.1002/cncr.34023
pmc: PMC9298928
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
654-664Subventions
Organisme : AstraZeneca
Organisme : Merck
Informations de copyright
© 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Oncol Nurs Forum. 2010 May;37(3):251-2
pubmed: 20439209
JNCI Cancer Spectr. 2019 Oct 09;3(4):pkz084
pubmed: 31840133
Gynecol Oncol. 2013 Dec;131(3):503-7
pubmed: 24060416
Gynecol Oncol. 2015 Mar;136(3):491-7
pubmed: 25455734
J Clin Oncol. 2003 Apr 1;21(7):1383-9
pubmed: 12663731
J Natl Cancer Inst. 2009 Jan 21;101(2):80-7
pubmed: 19141781
J Natl Cancer Inst. 2013 Jun 5;105(11):823-32
pubmed: 23539755
Gynecol Oncol Rep. 2017 Nov 15;22:100-104
pubmed: 29201989
Obstet Gynecol. 2013 Nov;122(5):1025-1032
pubmed: 24104782
J Clin Oncol. 2007 Sep 1;25(25):3985-90
pubmed: 17761984
N Engl J Med. 2002 May 23;346(21):1609-15
pubmed: 12023992
Gynecol Oncol. 2012 Apr;125(1):19-24
pubmed: 22108636
Int J Gynecol Cancer. 2014 Jul;24(6):1003-9
pubmed: 24887442
J Clin Oncol. 2021 May 20;39(15):1631-1640
pubmed: 33560870
Clin Trials. 2014 Oct;11(5):565-75
pubmed: 24902923
J Clin Oncol. 2014 May 1;32(13):1302-8
pubmed: 24637997
Cancer. 2022 Feb 15;128(4):654-664
pubmed: 34787913
Gynecol Oncol. 2010 Oct;119(1):7-17
pubmed: 20692025
Mayo Clin Proc. 2012 Oct;87(10):935-43
pubmed: 23036669
N Engl J Med. 2002 May 23;346(21):1616-22
pubmed: 12023993
J Oncol Pract. 2016 Dec;12(12):e974-e980
pubmed: 27601509
J Clin Oncol. 2008 Mar 10;26(8):1331-7
pubmed: 18268356
Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):421-31
pubmed: 21831023
Gynecol Oncol. 2015 May;137(2):280-4
pubmed: 25735256
Pain. 2002 Oct;99(3):385-396
pubmed: 12406513
Gynecol Oncol. 2016 Dec;143(3):611-616
pubmed: 27697287
Patient Educ Couns. 2018 Feb;101(2):285-294
pubmed: 28935442
JAMA Oncol. 2016 Nov 01;2(11):1427-1433
pubmed: 27442965
J Natl Compr Canc Netw. 2017 Jan;15(1):9-20
pubmed: 28040716
J Pathol. 2001 Nov;195(4):451-6
pubmed: 11745677
World J Obstet Gynecol. 2014 May;3(2):71-77
pubmed: 26478860
Am J Surg Pathol. 2006 Feb;30(2):230-6
pubmed: 16434898
Am J Public Health. 2014 Jun;104 Suppl 3:S423-31
pubmed: 24754663
J Med Genet. 2014 Feb;51(2):108-13
pubmed: 24277755
Ann Oncol. 2013 Dec;24 Suppl 10:x16-21
pubmed: 24265397
Hum Pathol. 2011 Jul;42(7):918-31
pubmed: 21683865
Adv Cancer Res. 2020;146:139-166
pubmed: 32241387
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Obstet Gynecol. 2015 Apr;125(4):833-842
pubmed: 25751200
JAMA. 2018 Aug 14;320(6):597-598
pubmed: 30120466
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Gynecol Oncol. 2017 Jun;145(3):486-492
pubmed: 28372872
Ann Surg Oncol. 2016 May;23(5):1530-6
pubmed: 26790670
Clin Cancer Res. 2016 Dec 1;22(23):5909-5914
pubmed: 27521449
Am J Surg. 2012 Apr;203(4):415-22
pubmed: 21996347
Lancet Oncol. 2020 May;21(5):699-709
pubmed: 32305099
Gynecol Oncol. 2015 Jan;136(1):11-7
pubmed: 25449311
Acta Obstet Gynecol Scand. 2009;88(4):449-56
pubmed: 19266357
J Clin Oncol. 2016 Aug 20;34(24):2888-98
pubmed: 27325851
Int J Gynecol Pathol. 2004 Jan;23(1):35-40
pubmed: 14668548
Am J Pathol. 2016 Apr;186(4):733-47
pubmed: 27012190
CA Cancer J Clin. 2019 Jul;69(4):280-304
pubmed: 31099893
J Clin Oncol. 2002 Jan 15;20(2):528-37
pubmed: 11786583
Curr Obstet Gynecol Rep. 2012 Mar;1(1):1-9
pubmed: 22506137
Fertil Steril. 2016 Dec;106(7):1763-1771.e1
pubmed: 27678034
Obstet Gynecol. 2016 Jan;127(1):81-89
pubmed: 26646132
J Natl Cancer Inst. 2017 Dec 1;109(12):
pubmed: 30053074
JAMA. 2004 Jun 9;291(22):2720-6
pubmed: 15187053
J Pain Symptom Manage. 2002 Nov;24(5):481-93
pubmed: 12547048
Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):539-545
pubmed: 30487136
J Clin Oncol. 2016 Aug 20;34(24):2874-80
pubmed: 27325865
J Womens Health (Larchmt). 2015 Nov;24(11):899-906
pubmed: 26208166
J Clin Oncol. 2004 Nov 15;22(22):4626-31
pubmed: 15542812
J Oncol Pract. 2019 Nov;15(11):585-590
pubmed: 31509483
J Oncol Pract. 2016 Jun;12(6):556-63
pubmed: 27189356
World J Obstet Gynecol. 2016;5(2):187-196
pubmed: 29520338
Gynecol Oncol. 2017 Jul;146(1):3-10
pubmed: 28372871
Transl Behav Med. 2018 May 23;8(3):503-508
pubmed: 29800404
J Oncol Pract. 2014 May;10(3):206-8
pubmed: 24839284
J Clin Oncol. 2019 May 20;37(15):1305-1315
pubmed: 30964716
Trials. 2016 Jan 09;17:17
pubmed: 26745891